TABLE 3.
Baseline and 12-wk fasting serum analytes in women with ovarian or endometrial cancer who consumed the ACS and KD1
| ACS (n = 20) | KD (n = 23)2 | |||
|---|---|---|---|---|
| Week 0 | Week 12 | Week 0 | Week 12 | |
| Glucose, mg/dL | 102.2 ± 3.6 | 98.7 ± 2.5 | 102.3 ± 3.9 | 93.0 ± 3.3 |
| Insulin,3 µU/mL | 14.2 ± 2.2 | 12.1 ± 1.5 | 10.5 ± 1.4 | 6.7 ± 0.9** |
| C-peptide, ng/mL | 3.2 ± 0.3 | 3.0 ± 0.3 | 2.8 ± 0.3 | 2.0 ± 0.3** |
| β-hydroxybutyrate, mmol/L | 0.20 ± 0.02 | 0.25 ± 0.04 | 0.36 ± 0.15 | 0.91 ± 0.16*** |
| IGF-I,4 ng/mL | 116 ± 13.7 | 111 ± 13.4 | 120.3 ± 8.9 | 100.7 ± 9.6 |
| IGFBP-1,4 µg/mL | 1.8 ± 0.2 | 1.7 ± 0.2 | 1.8 ± 0.2 | 2.1 ± 0.3 |
1
Values are means ± SEMs. **P < 0.01; ***P < 0.001 compared with week 12 ACS. P values from ANCOVA, adjusted for baseline condition. ACS, American Cancer Society diet; IGF-I, insulin-like growth factor I; IFGBP-1, insulin-like growth factor binding protein 1; KD, ketogenic diet.
2
Serum samples were not available for 2 participants.
3
One participant receiving exogenous insulin and 1 outlier excluded.
4
One outlier excluded.